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Glioblastoma (GBM) is the most common and most aggressive primary brain malignancy
and, as it stands, is virtually incurable. With the current standard of care, maximum feasi-
ble surgical resection followed by radical radiotherapy and adjuvant temozolomide, survival
rates are at a median of 14.6 months from diagnosis in molecularly unselected patients
(1). Collectively, the current knowledge suggests that the continued tumor growth and
survival is in part due to failure to mount an effective immune response. While this toler-
ance is subtended by the tumor being utterly “self,” it is to a great extent due to local and
systemic immune compromise mediated by the tumor. Different cell modalities including
lymphokine-activated killer cells, natural killer cells, cytotoxic T lymphocytes, and trans-
genic chimeric antigen receptor or αβ T cell receptor grafted T cells are being explored to
recover and or redirect the specificity of the cellular arm of the immune system toward
the tumor complex. Promising phase I/II trials of such modalities have shown early indica-
tions of potential efficacy while maintaining a favorable toxicity profile. Efficacy will need
to be formally tested in phase II/III clinical trials. Given the high morbidity and mortality of
GBM, it is imperative to further investigate and possibly integrate such novel cell-based
therapies into the current standards-of-care and herein we collectively assess and critique
the state-of-the-knowledge pertaining to these efforts.
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INTRODUCTION
Immunotherapy refers to manipulation of a patient’s immune
system to treat disease (2). Tumor-associated antigens (TAAs)
comprise unique tumor-specific or tumor-associated molecules
that are undetectable or modestly expressed on normal tissues but
are more avidly represented on tumor cells and or their microenvi-
ronment. TAAs could be immunogenic because they are expressed
at higher than normal levels for the developmental stage, or they
contain a novel peptide sequence generated by gene mutation or
rearrangement, and thus serve as attractive targets for immune
based-cellular therapies (3).
Active and passive immunotherapies are two different strate-
gies used to generate anti-tumor activity. Active immunotherapy
has generally employed specific tumor vaccines and non-specific
immune stimulants. The basis of tumor vaccine therapies is
that administration of tumor-specific or TAAs in the context of
immune costimulation induces tumor-specific immunity, result-
ing in anti-tumor effects. Cancer vaccines aim to induce a response
predominated by cytotoxic T lymphocytes (CTLs) that are able
to recognize such endogenous antigens (4). This approach can be
especially effective in cases in which the tumor expresses an antigen
but fails to activate the immune system. To elicit CTL responses,
the molecules must be expressed in professional antigen presenting
cells (APCs), or the tumor cell itself must be modified to express
APC characteristics and function (5).
Passive immunotherapy is also referred to as adoptive
immunotherapy. Adoptive immunotherapy involves directly
transferring effector immune cells to a host in order to induce anti-
tumor activity. Non-specific effector cells such as natural killer
(NK) cells and lymphokine-activated killer (LAK) cells are innately
reactive as they recognize cell surface abnormalities, such as low
expression of major histocompatibility complex (MHC) class I
molecules or carbohydrate abnormalities. T cells recognize for-
eign peptides presented on the cell surface by MHC molecules (6).
While T cells specific for tumor antigens can be identified within
the tumor tissues or elsewhere, most are present at a low frequency,
many have receptors with low avidity for the tumor antigens,
and some are commonly anergic. One strategy to overcome these
limitations is to activate T cells ex vivo to circumvent these lim-
itations and to overcome suppressive factors present in vivo thus
augmenting the anti-tumor activity (7).
This article will describe the rationale for and state of current
cell-based therapy strategies that are being used and investigated
to treat glioblastoma. The scope of research being conducted is
vast, but we will review some benefits and challenges for these
approaches. Additionally, future challenges and directions in cell-
based therapies for glioblastoma will be discussed. The hope is to
present an overview of this novel field as a new adjunct for the cur-
rent standard treatment of this highly malignant and fatal disease.
RATIONALE FOR IMMUNOTHERAPY IN GLIOBLASTOMA
The very poor outcomes for glioblastoma (GBM) using standard-
of-care treatment call for novel biologically based interven-
tions. The increasing use of immunotherapeutics stems from the
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growing body of knowledge of how the immune system inter-
acts with cancer cells and their induced microenvironment. The
immune system has both host-protective and tumor-promoting
functions, a concept termed cancer immunoediting. This con-
cept describes the immune system’s role in immunosurveillance,
maintaining tumor latency, and tumor immune escape mecha-
nisms (8). Tumor cells escape recognition by the immune system
by employing a number of strategies including antigen mutation,
down regulation and deletion of target antigens, and selective sur-
vival of certain antigen negative or positive tumor subpopulations
(9, 10). These strategies are particularly relevant to GBM, which
is known to be heterogeneous with varying antigen expression
profile within single tumors and between patients (11, 12).
Glioblastoma has a number of immunosuppressive properties,
and enhancing the host’s immune response against tumor repre-
sents a rational approach to reverse this deficiency. Several mech-
anisms contribute to this immunosuppression. More specifically,
GBM tumor cells secrete a myriad of immune-inhibitory mole-
cules such as the transformation growth factor receptor (TGF) β.
Increased concentrations of these factors decrease host anti-tumor
response and may promote tumor invasion (13). GBM cells are
also inefficient in antigen processing, especially in cancer stem
cells (CSCs) isolated from this tumor type. This may render GBM
cells resistant to the T cell-mediated immune reactions (14).
A subset of GBM cells expressing the surface antigen CD133
exhibit properties of stem cells and the ability to initiate a tumor
(15). GBM-associated CSCs have immunosuppressive properties
and show resistance to standard therapies. Studies on whether
CSCs in solid tumors are more chemo- and or radio-resistant than
the bulk population are most advanced for brain cancer. GBM-
associated CSCs have immunosuppressive properties and show
resistance to standard therapies. CD133+ cells are more resis-
tant to ionizing irradiation than CD133− cells. Expansion in the
CD133+ subset was found following irradiation. CD133+ cells
preferentially activate the DNA damage checkpoint response more
effectively than CD133− cells. CSC population appears to have
evolved a more efficient DNA damage repair system than the bulk
of the tumor, conferring resistance to radiation treatment (16).
Glioblastoma-associated CSCs participate in tumor-mediated
immunosuppression by both secreted and membrane-associated
mechanisms and inhibit both innate and adaptive immunity.
CD133+ CSCs cells also inhibit T cell proliferation and activa-
tion, induce regulatory T cells, and trigger T cell apoptosis (17).
These immunosuppressive properties were diminished on altering
the differentiation of the cancer-initiating cells (18). Additionally,
CSCs recruit monocytes to the tumor microenvironment and con-
tribute to the conversion of monocytes to an immunosuppressive
phenotype by a variety of secreted factors. Such macrophages then
act in a protumoral manner by enhancing invasiveness, increasing
tumor angiogenesis, and potentiating tumor-mediated immuno-
suppression by a variety of secreted products, while GBM CSCs
impede their phagocytic ability (19).
Steroid and radiation therapy for GBM also enhances immuno-
suppression in these patients (20). As therapy with temozolomide
and radiation therapy have now become the standard of care (1),
this therapy in the treatment of high-grade gliomas (HGGs) has
been associated with lower CD4 counts in some patients. Those
with lower CD4 counts were shown to have decreased survival due
to earlier progression of their GBM (21).
ADVANTAGES OF CELLULAR THERAPEUTICS
Cell therapy has substantial theoretical and practical advantages
over traditional chemotherapy and other immunotherapy strate-
gies. Results from completed phase I/II clinical trials with epider-
mal growth factor receptor (EGFR) monoclonal antibodies, tumor
cell,or dendritic cell (DC) vaccines were encouraging,demonstrat-
ing disease stabilization, and prolonged patient survival (22–26).
With respect to EGFR monoclonal antibodies, however, one phase
I/II trial did not suggest the addition of an anti-EGFR monoclonal
antibody had improved efficacy over baseline therapies for pro-
gressive disease (27). Mutations in the EGFR receptors on GBM
cells can block the action of these therapies in a subset of tumor
cells (28).
These trials have highlighted some of the limitations of current
approaches. Antibodies – unlike T cells – do not cross the blood
brain barrier (BBB), actively migrate through microvascular walls,
or penetrate the core of solid tumors to exert their anti-tumor
activity. The in vivo induction of antigen-specific T cells using anti-
gen loaded DC is often not reproducible, because tumor-specific
T cells are either present at very low frequency or are anergized.
Tumor cell vaccines contain ubiquitous as well as TAAs and may
induce immune responses to normal brain tissue. One strategy to
overcome the current limitations of GBM targeted immunother-
apies is adoptive T cell transfer in which tumor-specific T cells are
prepared ex vivo and then transferred into patients (24–26).
In adoptive T cell transfer, it is necessary to identify only a small
number of anti-tumor cells with the appropriate properties that
can then be expanded to large numbers ex vivo for subsequent
adoptive transfer. In vitro assays can identify the exact populations
and effector functions required for cancer regression, which can
then be selected for expansion. The cells can be activated in the
laboratory free from endogenous inhibitory factors and thus can
be induced to exhibit the required anti-tumor effector functions.
It is possible to manipulate the host before cell transfer to provide
an optimal environment for the transferred cells.
Cell-based therapies provide strategies to overcome these
immune effects. Cell-based therapies for the treatment of glioblas-
toma have evolved from non-specific to more tumor-specific over
time (Table 1). Early work introduced NK cells, LAKs, and gamma-
delta (γδ) T cells as ways to expand and activate the immune system
and tip the balance toward an anti-tumor effector function in
the face of a substantially immunosuppressive tumor microenvi-
ronment. Other newer approaches use tumor specificity to target
tumor-specific antigens using virus specific CTLs and chimeric
antigen receptor (CAR) T cells.
CELLULAR THERAPEUTIC ENTITIES FOR GLIOBLASTOMA
NATURAL KILLER CELLS
Natural killer cells are a subtype of cytotoxic lymphocytes that
participate in the innate immune system. NK cells do not express
T cell receptors, T cell marker CD3, or surface immunoglobulin B-
cell receptors, but they usually express surface markers CD16 and
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Table 1 | Modalities of cellular therapies for GBM.
Cellular product Description Mechanism of killing Advantages Disadvantages Reference
Natural killer (NK)
cells
Innate immune subset of
cytotoxic T cells
CD16 and CD56 positive
Anti-tumor and antiviral killing
Identify cells lacking
MHC-1 for killing
Inhibitory signals are
not engaged, activating
targeted killing
Tumor specimen not
necessary for
expansion
Short expansion time
Non-specific killing
Can inhibit
virotherapy
Miller et al. (29),
Campbell and
Hasegawa (30),
Dix et al. (33),
Miller et al. (35)
Lymphokine-
activated killer
(LAK) cells
Autologous peripheral
lymphocytes activated with IL-2
in vitro to become anti-tumor
effectors
Unclear MHC-independent
killing
Non-specific killing Dillman et al. (37)
Injected with IL-2 when
administered to patients
γδT cells Innate effectors that display
alternative T cell receptors to
αβT cells
Unclear MHC-independent
killing
Non-specific killing Bryant et al. (40)
Donor
lymphocyte
infusion (DLI)
Infusion of donor lymphocytes
for anti-tumor effect
Unclear Graft versus tumor
effect
Risk for
graft-versus-host
disease
Collins et al. (41),
Hasskarl et al. (42)
Allogeneic mixed
lymphocyte
reactive T cells
Lymphocytes from
histoincompatible allogeneic
donors are mixed with patient
lymphocytes and infused
Targeted killing due to
sensitization of
allogeneic cells to
patient MHC
Easy to produce Risk for alloreactivity Amrolia et al. (46)
Tumor infiltrating
lymphocytes
(TILs)
Cytotoxic lymphocytes
obtained from tumor site
Through TCR
engagement
Tumor-specific killing
Cells track effectively to
CNS
Cells required from
tumor or tumor-
draining lymph
nodes
Kruse et al. (50),
Plautz et al. (53)
Expanded in presence of IL-2
and original tumor
Patient may have
preconditioning with radiation
or chemotherapy
Cytotoxic T
lymphocytes
Autologous T cells activated
and expanded
TCR engagement of
antigen in the context
of an MHC molecule
leads to cytotoxic killing
Targeted killing with
specific TCRs
MHC-restricted
operation
Dudley et al. (55),
Shu et al. (57), Ghazi
et al. (65), Ahmed
(66)
Viral or tumor antigens may be
targeted
Very effective for
virus-driven
malignancies
Anergy at low
frequency
Time to production
can be limiting
Tregs at tumor site
can inhibit function
Can be engineered with
αβTCRs or CARs to
target tumor antigens
Chimeric antigen
receptor (CAR) T
cells
Chimeric molecule
Extracellular monoclonal
antibody specific for tumor
antigen
Intracellular T cell signaling
domain
Binding of
antigen-specific domain
initiates T cell-derived
signaling which
promotes T cell
activation and killing
MHC-independent
killing
Tumor specificity
Shorter time to
production than CTLs
Off-target effects
can occur
Limited survival
in vivo
Eshhar et al. (72, 73)
CD56. They have both anti-tumor and antiviral killing capabilities
(29). They kill in an human leukocyte antigen (HLA)-unrestricted
manor. Mature NK cells identify normal cells by their expression of
inhibitory receptors that recognize MHC-I. When these inhibitory
receptors encounter MHC-I on normal cells, they arrest tyro-
sine kinase-based activation signals. When an NK cell identifies
a cell lacking MHC-I, inhibitory receptors are not engaged, and
activating signals trigger targeted attack on these cells (30).
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Natural killer cells can be activated and expanded ex vivo
for adoptive immunotherapy. Adoptive immunotherapy with
expanded autologous NK cells has resulted in partial responses
with minimal toxicity in lymphoma and breast cancer (31). Autol-
ogous NK cells have been selectively expanded from PBMCs for
patients with high-grade glioma. In the presence of IFN-β as a
means to improve NK-mediated cytotoxicity, they were adminis-
tered intralesionally and IV. 9/16 treatment courses in 9 patients
resulted in SD or a measurable response after 4 weeks without
severe toxicity (32). Adoptive immunotherapy with NK cells is
thought to have several advantages when compared using LAK
cells or CTLs. Firstly, tumor specimens are not necessary for autol-
ogous NK cell expansion. Additionally,NK cells can be expanded in
a relatively shorter time than CTLs and exhibit more robust cyto-
toxicity compared with LAK cells (32). As with other cellular effec-
tors, the immunosuppressive environment of malignant gliomas
suppresses NK activity; T cells from patients with gliomas pro-
duce decreased amounts of IL-2 and IFN-γ. These two cytokines
are important for the generation of NK activity, and as a result NK
function may be impaired in these patients (33).
Natural killer cells have both antiviral and anti-tumor func-
tions, and they may inhibit the efficacy of virotherapy by pro-
moting enhanced tumor cell killing. Upon infection by oncolytic
herpes simplex virus, increased expression of certain cell surface
proteins can lead to an increase in NK cell activation within the
tumor microenvironment. NK cells then kill viral cells, resulting
in decreased viral titers and potentially decreasing the efficacy of
viral oncolysis (34). Numerous strategies are being investigated to
improve NK cell ability to attack cancer cells in vivo, one of which
is using haploidentical NK cell infusions (35).
LYMPHOKINE-ACTIVATED KILLER CELLS
In vitro, high concentrations of IL-2 can activate a subpopula-
tion of peripheral CD8+ cells to become non-specific tumoricidal
effectors; LAK cells. LAK cells can lyse NK cell resistant, fresh, or
cultured tumor target cells in vitro, including malignant gliomas
and other primary brain tumors. LAK cells and IL-2 have been
safely administered within the CNS resulting in improved long-
term survival in patients with recurrent glioma (36). Significant
biologic changes also occurred in these patients including regional
eosinophilia and extensive lymphocytic infiltration. In a phase II
trial of 33 patients with GBM treated with intralesional autologous
LAK cells after initial primary treatment, those with higher doses
of LAK cells had longer survival, and overall survival was encour-
aging compared to controls. Patients on corticosteroids prior to
leukapheresis had a lower number of NK cells harvested and lower
overall survival (37). LAK cells are also vulnerable to inhibitory
molecules expressed by GBM cells (38).
GAMMA-DELTA T CELLS
Gamma-delta T cells are a subset of T cells that express alter-
native, clonally distributed T cell receptors (TCRs) and function
as innate effectors and therefore are restricted in TCR diversity.
Compared to αβ T cells, they do not target specific peptide anti-
gens and are not constrained by the selectivity and restriction of
the MHC. Although γδ T cells absolute counts are decreased and
their proliferative capacity is decreased in the setting of GBM, they
can be expanded and activated ex vivo and have shown the ability
to recognize and kill glioma cells in vitro while sparing cultured
normal astrocytes (39). Expanded and activated γδ T cells can
mediate killing of GBM and reduce tumor progression in mouse
models (40). However, to date, there have been no human clinical
applications to date for treatment of brain tumors.
DONOR LYMPHOCYTE INFUSION AND ALLOGENIC MIXED LYMPHOCYTE
REACTIVE T CELLS
Adoptive immunotherapy with donor lymphocyte infusions
(DLIs) after hematopoietic stem cell transplant (HSCT) can effec-
tively augment the graft-versus-leukemia (GVL) effect and effec-
tively eliminate residual disease, especially in CML (41). Its GVL
effects make DLI currently one of the most effective strategies
for patients with recurrent hematological malignancies after allo-
geneic HSCT (42). Application of DLI is limited by the develop-
ment of graft-versus-host disease (GVHD), thus DLI is not used
routinely used for prophylaxis of relapse after allogeneic HSCT
(43). Many strategies have been developed to promote anti-tumor
effects of DLIs while decreasing the incidence of GVHD. These
include CD8+ cell depletion of DLIs (44), apoptosis regulation
(45), and selectively deplete the T cell product of alloreactive cells
that express activation markers in response to alloantigen (46).
Due to potential and probable risks and limitations application of
DLI in the context of GBM has not been effectively explored.
Lymphocytes derived from histoincompatible allogenic human
blood donors may also be combined with the patient’s irradi-
ated lymphocytes. A mixed lymphocyte reaction sensitizes the
allogeneic donor’s peripheral blood mononuclear cells toward
patient’s MHC. Since MHC proteins expressed on patient lympho-
cytes are also expressed on brain tumor (47) but not on normal
brain neurons, astrocytes, or oligodendrocytes (48), the tumor-
bearing host MHC offers a means for targeted, selective killing by
CTLs sensitized to them.
Additionally, if injected directly into the CNS, alloreactive CTLs
may be protected from host immune cells long enough to lyse tar-
get cells due to the nature of immune responses in the CNS (49). All
these features make this technique a promising strategy for brain
tumor therapy. In one study, five patients were infused with intra-
cavitary allogeneic mixed reactive T cells to recurrent gliomas. Two
had no evidence of disease and three were alive 28 months after
initiation of therapy. Alloreactive CTL treatment was efficacious
either when one MHC-disparate donor provided effector CTL sev-
eral times, or multiple MHC-disparate donors provided effector
CTL during the treatment period (50).
TUMOR INFILTRATING LYMPHOCYTES
Tumor infiltrating lymphocytes (TILs) are primarily CTLs which
recognize proteolytically cleaved intracellular tumor antigen
fragments which have become associated with specific MHC-I
antigens on the cell surface (49). Expanded TILs have cytolytic
activity against the original tumor and in contrast to LAK cells
the killing is MHC class I restricted. They are selectively expanded
from either tumor or draining lymph node cells via IL-2, then
re-stimulated with irradiated or killed tumor cells to maintain
T cell specificity. The complex is recognized by the TCR of spe-
cific T lymphocytes TILs are relatively specific in terms of their
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cytotoxicity to tumors, due to the requirement for the presence of
tumor antigen fragments associated with specific classes of MHC-
I antigens, and therefore have potential advantages over LAK cells
in terms of tumor specificity and cytotoxicity (51). Condition-
ing the recipient with chemotherapy and/or radiation prior to
adoptive transfer of these cells increases the response to adoptive
immunotherapy with TILs (52). Other advantages of this strategy
include minimal clinical toxicity (in comparison with LAK cells)
(53) and that effector function can be easily measured by radioiso-
tope release assays. Indeed, local infusion of autologous TILs
and rIL-2 has been done without severe toxicity in patients with
recurrent gliomas (51). TILs have been used to treat melanoma
metastatic to the brain with very favorable responses. This is clear
evidence that TILs effectively track to the CNS (54). Technical
issues with producing tumor-specific T cells from brain tumor
excision samples currently present a major barrier to conducting
clinical trials using TILs in glioma – the minority of biopsy speci-
mens yield satisfactory T cell populations, and the process is labor
and time intensive (55).
CYTOTOXIC T LYMPHOCYTES
Tumor-reactive T cells arise in cancer patients and infiltrate their
tumors but are not effective because of tumor-induced functional
defects. In general, CTLs represent a more targeted strategy for
adoptive immunotherapy. In contrast to NK cells, T cells recog-
nize targets through an antigen-specific TCR and interact with
targets only if HLA MHC antigens are also recognized. Develop-
ing successful CTL therapies depends on the availability of specific
antigens as targets and efficient methods for T cell activation and
expansion. Both viral and tumor-specific antigens can be used as
targets for CTLs.
Autologous T cells can be activated and expanded with a mono-
clonal antibody against the TCR to create therapeutically effective
T cells from tumor-bearing hosts. These can then be re-infused
into the host therapeutically. Lymph nodes draining progres-
sively growing tumors are an optimal source of T cells that are
sensitized to specific tumor antigens (56). Ex vivo activation of
tumor-draining LN cells with anti-CD3 monoclonal antibody or
bacterial superantigens induces potent effector function (57). This
strategy has been used in patients with newly diagnosed malig-
nant gliomas after surgery and radiation therapy. Several objective
clinical responses occurred with 4/12 patients showing partial
responses and no long-term toxicity (25).
Since latent viruses are thought to be controlled in immuno-
competent hosts by CTLs (58), infusion of T cells that target
these viruses can offer effective treatment for virus-driven lympho-
proliferation and malignancies in immunocompromised patients.
Most extensively, EBV-mediated lymphoproliferative diseases and
malignancies have been targeted for adoptive immunotherapy
with CTLs. Use of CTLs for EBV-driven post-transplant lympho-
proliferative diseases (59), lymphomas (60), and nasopharyngeal
carcinomas (61) have been utilized with various degrees of suc-
cess. A large percentage of GBM have been shown to express
the CMV immunodominant proteins pp65 and IE1–72 as well
as CMV nucleic acid detected by in situ hybridization (62–64).
CMV-specific CTLs have thus been expanded ex vivo from CMV
seropositive GBM patients and recognize and kill CMV-expressing
autologous tumor cells (65). This has thus prompted the use of
CMV-specific CTLs as a therapeutic modality (66) or as a plat-
form for CAR expression (67). CD133, a stem-like cell marker
expressed in the glioma cells that is believed to lead to tumorige-
nesis in the human brain, is an example of a TAA in glioma cells.
CD133+ CTLs have been shown to be cytotoxic to glioma stem
cells (68). This antigen has also been targeted by ex vivo expansion
of CD 133+/DC hybrid cells that stimulate CTLs and have shown
to be effective in killing glioma cells (69).
As an alternative to generating tumor antigen-specific T cells
for treatment of malignancies using APCs, genetic modification
of T cells to express a tumor antigen-specific αβTCRs or CARs has
gained substantial interest and produced successes (70, 71). One
approach has been to produce T cells with novel receptors by intro-
duction of chimeric receptors that have antibody-based external
receptor structures and cytosolic domains that encode signal trans-
duction modules of the TCR (72); CARs. These constructs can
function to retarget T cells in vitro in an MHC unrestricted man-
ner to attack the tumor while retaining MHC-restricted specificity
for the endogenous TCR.
CHIMERIC ANTIGEN RECEPTOR T CELLS
Tumor-specific T cells can be created by genetically modifying T
cells with specificity to express tumor-specific CARs. CARs, which
are artificial molecules custom made by fusing an extracellular
variable domain derived from a high-affinity monoclonal antibody
specific for a TAA of interest to an intracellular signaling domain
usually derived from the zeta-signaling chain of the TCR (73). On
encountering the specific antigen by the extracellular antibody-
derived domain, the T cell-derived signaling domain initiates an
intracellular signal that results in T cell activation.
T cells with CARs have many potential advantages over
immunotherapies based on monoclonal antibodies or T cells
alone. CARs recognize antigens in an HLA-independent man-
ner, and thus overcoming a major limitation of the αβ TCR,
which is limited by MHC restriction. CARs are able to circum-
vent some mechanisms by which tumors avoid MHC-restricted T
cell recognition, such as down regulation of MHC molecules (74).
CAR-expressing T cells are more likely to eradicate tumor cells
than antibodies alone, since they can migrate through microvas-
cular walls, extravasate, and penetrate the core of solid tumors to
exert their cytolytic activity, and sequentially kill a multiplicity of
target cells (75). They react better to modestly expressed tumor
targets because they can recruit additional components of the
immune system and amplify the anti-tumor immune response.
They broaden the range of antigens recognizable by T cells to
include carbohydrate and glycolipid antigens. CARs can reliably
generate T cells in a relatively short time for clinical usage, typically
10–15 days (75).
IL-13 receptor alpha 2 (IL13Rα2), human epidermal growth
factor receptor 2 (HER2), and Ephrin type A receptor 2 (EphA2)
are all glioma-specific antigens that provide targets for CAR-based
immunotherapy (76–78). The former is currently being explored
in a clinical trial infusion autologous CAR T cells clones into resec-
tion cavities of GBM (79). T cells from GBM patients have been
genetically engineered to be rendered HER2 specific. These effec-
tor cells recognized autologous HER2-positive GBMs including
their CD133-positive stem cells in vitro and had potent anti-tumor
activity against both killed CD133-positive and CD133-negative
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cells derived from primary HER2-positive GBMs (80). T cells
engineered to target IL13Rα2 have also shown tumor recogni-
tion and anti-tumor effector function (81). A clinical trial co-
targeting HER2 and CMV pp65 using autologous bispecific CAR
CTLs is currently underway in our center (67). T cells engi-
neered with CARs against such GBM-specific antigens provide
promising immunotherapeutic approaches for the treatment of
GBM. Another current phase I/II clinical trial is investigating the
safety and effectiveness of autologous CARs targeting EGFRvIII in
malignant gliomas (82).
MISCELLANEOUS; SPECIFIC CONSIDERATIONS
HELPER T CELLS
Many approaches to tumor immunotherapy in GBM have focused
on the CD8+ T cell effector functions. This is based on the obser-
vation that most tumor cells express some degree of MHC class I
but not class II molecules. Tumor models have demonstrated that
CD4+ tumor-reactive T cells have been shown to eradicate an
MHC class I positive but class II negative tumor in the absence of
CD8+ T cells for brain neoplasms, possibly showing the impor-
tance of interactions between CD4+ T cells and MHC class II
expressing tumor-associated cells (83). Because the mechanism of
CD4+ cells role in anti-tumor activity is not well defined, it is not
yet clear what type of in vitro assay would provide an optimal sur-
rogate marker of an effective immune responses. Currently, there
are no clinical applications to date using these cells to enhance
immunotherapy for GBM (25).
REGULATORY T CELLS
The main role of regulatory T cells (Tregs) is suppression of the
function of other cells. They express CD4 and CD25 on their cell
surface. Expression of the specific molecular marker FOXP3 is
increased when Tregs are activated. There is a significant increase
in the number of FOXP3-expressing CD4+CD25+ T cells within
GBM-infiltrating lymphocytes and in the peripheral blood of
patients with GBM (84). Treg depletion inhibits growth of GBM
tumors, but its efficacy may depend on tumor burden, as this
strategy has been shown to be more effective with smaller tumor
burdens earlier in the course of disease (85). Tregs also repre-
sent an increased fraction of the remaining CD4 compartment in
patients with glioblastoma. This increased Treg fraction correlates
with and is sufficient to elicit the characteristic manifestations of
impaired patient T cell responsiveness in vitro (86). Treg removal
eradicates T cell proliferative defects and reverses cytokine shifts,
allowing T cells from patients with malignant glioma to function
in vitro at levels equivalent to those of normal, healthy controls.
The collective restoration of these immune functions may allow
for enhancement of the antiglioma activity of adoptively trans-
ferred T cells (87). This increase in the frequency and fraction of
Tregs might play a role in modulation of the immune response
against malignant brain tumors. Methods to decrease or eliminate
Treg function may improve clinical results for immunotherapy
patients with GBM in the future.
LIMITATIONS OF CELLULAR THERAPEUTICS
Several obstacles, some posed by glioma cells or their microen-
vironment and others intrinsic to the cellular products, limit the
clinical efficacy of cellular therapeutics. Antigen presentation can
be impaired in malignancy by down regulation of the MHC class
I molecules on tumor cells, resulting in an inefficient recognition
by CD8+ anti-tumor lytic effectors; and the lack of the MHC class
II expression by most human tumors, limiting the simultaneous
engagement of CD4+ helper response at the tumor site alongside
CD8+ lytic response (88). We now have a better understanding of
the CD4+ suppressor/Tregs and their influence on the generation
of a productive anti-tumor immune response.
Additionally, tumors expressing tumor antigens and costimu-
latory molecules may not present the tumor peptides because of
the interference with the antigen-processing pathway by tumors
(89). The expression of peptide transporter molecules required for
peptide loading of MHC class I complexes can be downregulated.
Tumors may also inhibit cross-priming by professional APCs by
secreting inhibitory cytokines, which downregulates MHC class II
molecule expression on macrophages and DCs and prevents their
release of inflammatory cytokines (90).
The tumor microenvironment produces many obstacles to cell-
based therapies. Indeed, tumor cells can, directly or by influencing
the tumor microenvironment to play a protumoral role, manip-
ulate the host’s immune response for tumor-protective effects. T
cells in the microenvironment and their impact on tumor growth
may depend heavily upon the particular TIL subset. The major-
ity of CD4+ T cells favor tumor progression, while CD8+ T cells
favor tumor rejection (91). As mentioned above, Tregs inhibit the
effect of T cells to tumor or foreign antigens (92). Cytokines pro-
duced by tumors stimulate increased helper and Treg function
that decreases natural tumor immunity (93). When these regula-
tory cells are decreased in number, they increase the anti-tumor
effectors T cells (94). Suppressing these cells could enhance natural
tumor immunity and the ability to use adoptive strategies, while
their up regulation formidable obstacle to their effectiveness.
Cellular products do alternatively pose obstacles, the influ-
ence of which is progressively decreasing because of our improved
understanding of the influence of culture conditions on the quality
and reliability of generating effector cells. Problems such as limited
in vivo expansion post infusion are being resolved by optimizing
the cellular product (for example including enhanced signaling
domains in CAR T cells or infusion of more naïve phenotypes of
effectors) and or optimizing the receiving host by strategies such
as lymphodepletion or coadministration of immuno-stimulatory
cytokines.
CHALLENGES AND FUTURE INNOVATIONS
The BBB provides challenges in using immunotherapy for
the treatment of CNS malignancies. Isolation from systemic
circulation prevents delivery of T cells to the site of malignant
gliomas in the CNS. This barrier also provides immune privi-
lege that makes utilizing host immune responses in treatment of
these malignancies challenging (95). There is evidence that TILs
cross the BBB from studies showing success using TILs in the
treatment of CNS lymphoma (54) and post-transplant lympho-
proliferative disease (96–98). The delivery method of immune
cells to the tumor can circumvent the BBB. While many stud-
ies utilize direct injection of cells to the tumor site or systemic
injections, intranodal, intradermal, and intranasal, injections are
other options. Investigative comparison of these delivery strate-
gies should be performed to reach the optimal delivery route for
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effective GBM cellular therapy modalities. It has been shown that
the interaction between brain tumor cells and their associated
endothelium triggers T cell migration into the tumor microenvi-
ronment. Communication between the tumor cells and endothe-
lium with chemokines triggers this T cell migration (99). These
interactions should be explored as potential targets to augment
adoptive cell therapies.
Glioma cells are also considered to be poor APCs. They
have inadequate phosphorylation and cytoskeletal rearrangements
which are required for appropriate APC to T cell contacts and
stimulation of an immune response. T cells obtained from patients
with gliomas do not make sufficient contact with APCs and con-
sequently are not appropriately stimulated, which may explain
why only a limited number of T cells migrate into the tumor
sites (33).
Combining cell therapies with other novel treatment strategies
could lead to better outcomes for patients. One way this can be
done is through epigenetic modifiers. Epigenetics is the study of
stable genetic modifications that result in changes in gene expres-
sion and function without a corresponding alteration in DNA
Table 2 | Current clinical trials of adoptive cellular therapy for GBM.
Trial/phase Cell therapy
type
Description Sponsor/clinicaltrials.gov
identifier
Phase II study of intralesional adoptive
cellular therapy of GBM with
interleukin-2-stimulated lymphocytes
LAK cells Determine the feasibility, side effects, and toxicity
associated with intracranial cellular adoptive immunotherapy
comprising aldesleukin-stimulated lymphokine-activated
killer cells in patients with GBM
Hoag Memorial Hospital
Presbyterian/
NCT00331526 (completed)
Phase I study of cellular
immunotherapy for recurrent/refractory
malignant glioma using intratumoral
infusions of an allogeneic genetically
modified cytolytic T cells
αβT cells To study the safety and feasibility of giving intralesional
GRm13Z40-2, an allogeneic CD8( cytotoxic T cell line
genetically modified to express the IL-13 zetakine chimeric
immunoreceptor and the Hy/TK selection/suicide fusion
protein and found to be resistant to corticosteroids together
with aldesleukin in treating patients with malignant glioma
City of Hope Medical
Center/NCT01082926
Phase I study of recovery from
drug-induced lymphopenia using
CMV-specific T cell adoptive transfer
Vaccine/CMV-
specific
cytotoxic
lymphocytes
To evaluate if vaccinating patients with newly diagnosed
GBMs using CMV-DCs during recovery from therapeutic
temozolomide (TMZ)-induced lymphopenia with autologous
lymphocyte transfer (ALT) in patients that are seropositive
for CMV enhances the T cell response. To evaluate the
safety of ALT with CMV pp65-activated T cells in patients
with newly diagnosed GBMs during recovery from
therapeutic TMZ-induced lymphopenia
Duke University Medical
Center/NCT00693095
Phase I study to investigate autologous
lymphoid effector cells specific against
tumor-cells (ALECSAT) administered to
patients with GBM
Autologous T
cell infusion
To Assess safety and tolerability for administration of the
cell-based immunotherapy ALECSAT to patients with GBM
CytoVac A/S/NCT01588769
(completed)
Phase I/II study administering T cells
expressing anti-EGFRvIII CAR
CAR T cells To evaluate the safety and 6-month progression free survival
in patients with malignant gliomas expressing EGFRvIII
administered anti-EGFRlll CAR engineered peripheral blood
T cells, a non-myeloablative conditioning regimen, and
aldesleukin
National Cancer
Institute/NCT01454596
Phase I study of cellular
immunotherapy for recurrent/refractory
malignant glioma using genetically
modified autologous T cells
αβT cells To assess the feasibility and safety of cellular
immunotherapy utilizing ex vivo expanded autologous
CD8-positive T cell clones genetically modified to express
the IL-13 zetakine chimeric immunoreceptor and the Hy/TK
selection/suicide fusion protein in patients with recurrent or
refractory, high-grade malignant glioma
City of Hope Medical
Center/NCT00730613
(completed)
Phase I study of HER2 CAR-expressing
CMV-specific cytotoxic T cells in
patients with GBM (HERT-GBM)
CAR modified
CMV-specific
cytotoxic
lymphocytes
To evaluate the safety of autologous CMV-specific CTLs
genetically modified to express CARs targeting HER2 in
patients with HER2-positive GBM who have recurrent or
progressive disease after front line therapy
Baylor College of
Medicine/NCT01109095
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sequence (100). These modifiers can work separate and in addition
to conventional therapies or work to enhance conventional ther-
apies. For example, tumorigenicity of glioma stem cells can be
inhibited by inhibiting the JAK/STAT signaling pathway, and find-
ing ways to inhibit this and other pathways could have therapeutic
effects (101).
Glioblastoma microenvironment produces immunosuppres-
sive cytokines. Preoperative and postoperative plasma levels of
active and latent TGF-β are significantly higher in patients
with GBM than in plasma from normal controls (13). TGF-β
is a cytokine that can have inhibitory effects on the immune
system and proliferation and can allow cancers to become
more invasive. TGF-β may therefore contribute to depressing
the general immune defense system of glioblastoma patients,
which furthermore may support the immune surveillance of
the tumor. Selective inhibitors of the TGFbR-I kinase can
potentiate radiation responses in glioblastoma cells by coordi-
nately increasing apoptosis and cancer stem-like cells targeting
while blocking DNA damage repair, invasion, and angiogen-
esis (102). Alternatively, using human tumor antigen-specific
CTLs engineered to resist the inhibitory effects of tumor-
derived TGF-β by using a retrovirus vector in which the dom-
inant negative TGF-β type II receptor was modified and inef-
fective produced TGF-β-resistant CTLs that had a functional
advantage over unmodified CTLs in the presence of TGF-
β-secreting EBV positive lymphoma. These CTLs also had
enhanced anti-tumor activity (103). The potential value of this
approach in cell-based therapies is currently being explored
further (104).
Glioblastoma is the epitome of heterogeneity and targeted cell
therapies can become ineffective over time as tumors develop
antigen escape variants. This could develop because of the high
mutation rate in GBM, but might be intrinsic to the tumor cell
heterogeneity or induced by selective survival of target negative
cells after therapy. Overcoming this mechanism of resistance will
be necessary to improve response in patients. Along this line, there
are strategies in the development that could offset antigen escape
by co-targeting multiple TAA using cellular products grafted with
multiple CARs (10) or single CAR molecules that can mediated
bispecific activation and targeting of T cells (105).
Phase II clinical trials are needed to determine efficacy of
immunotherapies (Table 2). Designing these trials with effective
monitoring of immunotherapy and immune system-related end-
points to assess disease response can be challenging. The modified
Response Evaluation Criteria in Solid Tumors (RECIST) criteria
are a commonly used tool to assess solid tumor disease response to
therapeutic agents. In general, it relies on the presence of disease
on imaging at the beginning of a treatment, and uses enhancement
to gage response to the therapy (106). Since anti-tumor immune
responses may be delayed compared to conventional chemother-
apy and new or larger enhancing lesions soon after immune
therapy may represent immune cell infiltration, immune-related
response criteria (irRC) have been developed to incorporate these
principles (107). Immunotherapy can also induce serum or local
cellular responses, but immune response assays to define bio-
markers of immune response often have highly variable and often
non-reproducible results (108).
Lastly, while the overall safety of cell therapies has been
good, evaluating, and improving the safety of these techniques is
essential. Since the immune system is manipulated and activated,
there is a concern for pathologic immune activation. Overproduc-
tion of proinflammatory cytokines can occur as a result of T cell
triggering, a phenomenon known as the cytokine release syndrome
(109). Features of this syndrome include high-grade cyclical fevers
and hypotension, and it has been reported after infusion of CAR
T cells (110). One approach investigated to prevent adverse out-
comes is to incorporate a safety or “suicide” gene in the transferred
cells. A small molecule is administered in the event of an adverse
event activates a suicide-gene product and kills the transduced cell
by inducing apoptosis (45).
Cellular therapies are effective, potentially safe options for
GBM, they are complex and potentially quite expensive but could
improve the dismal outcomes while maintaining a very favorable
toxicity profile.
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